Novel Screening Methods and Interventions in Preeclampsia
Mészáros Balázs
Molecular Medicine Division
Dr. Várnai Péter
Szülészeti és Nőgyógyászati Klinika, Üllői úti részleg, előadóterem
2025-09-12 12:00:00
Pathobiochemistry
Dr. Ligeti Erzsébet
Dr. Valent Sándor
Dr. Keszthelyi Márton
Dr. Kozma Bence
Dr. Szathmári Miklós
Dr. Gerszi Dóra
Dr. Magyar Zoltán
The objective of my PhD work was to evaluate novel screening methods and treatments for preeclampsia, focusing on identifying predictive markers like the neutrophil-to-lymphocyte ratio (NLR) through meta-analyses and exploring the efficacy of pravastatin in preventing and treating the condition. By conducting these studies, I aimed to improve early detection and develop potential preventive strategies for high-risk patients.
For the NLR analysis, six studies were selected, encompassing a total of 2,469 patients. The meta-analysis revealed an effect size with a 95% confidence interval (CI) ranging from 0.641 to 1.523, and a prediction interval from 0.027 to 2.137.
For the evaluation of pravastatin, fourteen studies were identified, including 1,570 pregnant women who were administered either pravastatin or a placebo. Among these, five studies were included in the meta-analysis to assess the impact of pravastatin use before 20 weeks of gestation. The results indicated that pravastatin treatment led to a 61% reduction in the incidence of preeclampsia, a 68% decrease in premature births, a 45% reduction in IUGR among the newborns, and a 77% reduction in neonatal intensive care unit (NICU) admissions.
